Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial
- Category: Proteins and Peptides
- Published on Wednesday, 21 February 2018 09:31
- Hits: 1019
COURBEVOIE, France and HOUSTON, TX, USA I February 20, 2018 I Orano Med (formerly AREVA Med) and RadioMedix announced today the dosing of the first three patients in the AlphaMedix™ Phase 1 clinical trial. The objective of this Phase 1 is to determine safety, bio-distribution, and preliminary effectiveness of AlphaMedix™ in patients with somatostatin receptor positive neuroendocrine tumors (NETs).
“The extraordinary mobilization of Orano Med’s team, our RadioMedix partner, and Excel Diagnostics and Nuclear Oncology Center has allowed the dosing of these first three patients only a month after IND approval. It’s an important milestone, and we’re eager to see first results,” said Julien Dodet, Orano Med’s CEO.
The initial cohort of patients was given a single dose of AlphaMedix™, produced by Orano Med in Plano, Texas. If dose limiting toxicity is not seen after two months, the dosage will be increased for the second patient cohort.
AlphaMedix™ is a radiolabeled SSTR-targeting therapeutic investigational drug for treatment of NET patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb and serve as an in vivo generator of alpha-emitting particles. 212Pb isotope is particularly suitable for SSTR therapy applications based upon its half-life, energy and decay properties.
Dr. Ebrahim S. Delpassand, Chairman and CEO of RadioMedix, and Medical Director of Excel Diagnostics and Nuclear Oncology Center, added: “AlphaMedix™ has a strong potential to treat patients with NETs and overcome some of the limitations of the current therapies. If similar impressive results that we saw during preclinical studies can be translated in our clinical trial, AlphaMedix™ will have an important positive impact on survival and quality of life of our patients with NETs. The combination of Orano Med’s and RadioMedix’s expertise is a key asset to reach that objective.”
About Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. Most NETs strongly express somatostatin receptors (SSTRs).
More about Orano Med
Orano Med (formerly AREVA Med) is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212, a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing recognizing and destroying cancer cells while limiting the impact on nearby healthy cells. With its partners, Orano Med pursues the development of effective therapies to address patients’ needs. Orano Med is a subsidiary of Orano. More information about Orano Med: www.oranomed.com. Follow @Oranomed on Twitter
More about RadioMedix
RadioMedix, Inc. is a clinical-stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals for targeted radionuclide therapy in cancer. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for human clinical trials and probe development and small animal Molecular Imaging Facility for pre-clinical evaluation of radiopharmaceuticals in animal models. More information at www.radiomedix.com.
SOURCE: Orano Med